Figure 6.
(A) Both anti-VEGF mAb and SU1498 significantly decreased proliferation ability of EPCs cultured in GLP-1 10nM. Data are expressed as means ±SE; n=6, #P<0.05 vs. GLP-1 10 nM. (B) The neutralizing anti-VEGF mAb significantly inhibited expression of these EC-specific markers KDR, Flt-1, VE-cadherin and eNOS (1: Control group; 2: GLP-1 10nM group; 3: GLP-1 10nM + VEGFmAb 100 ng/ml group). (C) The KDR-specific tyrosine kinase inhibitor SU1498 significantly suppressed KDR, Flt-1, VE-cadherin and eNOS expression in EPCs (1: Control group, 2: GLP-1 10nM group, 3: GLP-1 10nM + SU1498 5 μM group).